标题
Akt inhibitors in clinical development for the treatment of cancer
作者
关键词
-
出版物
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 19, Issue 11, Pages 1355-1366
出版商
Informa Healthcare
发表日期
2010-09-16
DOI
10.1517/13543784.2010.520701
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Phase II trial of the novel oral Akt inhibitor perifosine in relapsed and/or refractory Waldenstrom macroglobulinemia (WM)
- (2017) I. M. Ghobrial et al. JOURNAL OF CLINICAL ONCOLOGY
- Combined mTOR and AKT inhibition in renal cell carcinoma (RCC).
- (2017) W. S. Holland et al. JOURNAL OF CLINICAL ONCOLOGY
- First-in-class phase I trial of a selective Akt inhibitor, MK2206 (MK), evaluating alternate day (QOD) and once weekly (QW) doses in advanced cancer patients (pts) with evidence of target modulation and antitumor activity.
- (2017) T. A. Yap et al. JOURNAL OF CLINICAL ONCOLOGY
- First-in-human phase I study of the oral PI3K inhibitor BEZ235 in patients (pts) with advanced solid tumors.
- (2017) H. Burris et al. JOURNAL OF CLINICAL ONCOLOGY
- Akt2 and Akt3 play a pivotal role in malignant gliomas
- (2011) H. Mure et al. NEURO-ONCOLOGY
- Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer
- (2010) Carlos H. Barrios et al. BREAST CANCER RESEARCH AND TREATMENT
- GSK690693 Delays Tumor Onset and Progression in Genetically Defined Mouse Models Expressing Activated Akt
- (2010) D. A. Altomare et al. CLINICAL CANCER RESEARCH
- The Efficacy of the Novel Dual PI3-Kinase/mTOR Inhibitor NVP-BEZ235 Compared with Rapamycin in Renal Cell Carcinoma
- (2010) D. C. Cho et al. CLINICAL CANCER RESEARCH
- Randomized Study of Lapatinib Alone or in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab-Refractory Metastatic Breast Cancer
- (2010) Kimberly L. Blackwell et al. JOURNAL OF CLINICAL ONCOLOGY
- MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted Drugs In vitro and In vivo
- (2010) H. Hirai et al. MOLECULAR CANCER THERAPEUTICS
- Genetic Alterations in the Phosphoinositide 3-Kinase/Akt Signaling Pathway Confer Sensitivity of Thyroid Cancer Cells to Therapeutic Targeting of Akt and Mammalian Target of Rapamycin
- (2009) D. Liu et al. CANCER RESEARCH
- Targeting the PI3K/AKT Pathway for the Treatment of Prostate Cancer
- (2009) D. Sarker et al. CLINICAL CANCER RESEARCH
- Antitumor activity of a novel antisense oligonucleotide against Akt1
- (2009) Heejeong Yoon et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- The level of AKT phosphorylation on threonine 308 but not on serine 473 is associated with high-risk cytogenetics and predicts poor overall survival in acute myeloid leukaemia
- (2009) N Gallay et al. LEUKEMIA
- Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3K/mTOR inhibition
- (2009) M. Breuleux et al. MOLECULAR CANCER THERAPEUTICS
- Prioritizing Comparative-Effectiveness Research — IOM Recommendations
- (2009) John K. Iglehart NEW ENGLAND JOURNAL OF MEDICINE
- Insulin Stimulates Adipogenesis through the Akt-TSC2-mTORC1 Pathway
- (2009) Hui H. Zhang et al. PLoS One
- Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells
- (2009) Saskia M. Brachmann et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Perifosine: Update on a novel Akt inhibitor
- (2009) Joell J. Gills et al. Current Oncology Reports
- Characterization of an Akt Kinase Inhibitor with Potent Pharmacodynamic and Antitumor Activity
- (2008) N. Rhodes et al. CANCER RESEARCH
- Mechanism and Management of AKT Inhibitor-Induced Hyperglycemia
- (2008) M.-C. Crouthamel et al. CLINICAL CANCER RESEARCH
- An activating mutation inAKT1in human prostate cancer
- (2008) Joost L. Boormans et al. INTERNATIONAL JOURNAL OF CANCER
- Phase II Study of Sunitinib Malate, an Oral Multitargeted Tyrosine Kinase Inhibitor, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane
- (2008) Harold J. Burstein et al. JOURNAL OF CLINICAL ONCOLOGY
- FBXW7 Targets mTOR for Degradation and Cooperates with PTEN in Tumor Suppression
- (2008) Jian-Hua Mao et al. SCIENCE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More